Literature DB >> 26901618

Pneumococcal conjugate vaccine in adults: Let's see what happens.

Peter R Paradiso1.   

Abstract

The recent recommendation for the use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults 65 y of age and older, provides a new tool for preventing disease in this at-risk population. The conjugate vaccine induces a T-cell dependent response, which distinguishes it from the polysaccharide vaccine and could provide the longer-term protection necessary to have a significant impact in this population.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26901618      PMCID： PMC4964835          DOI： 10.1080/21645515.2016.1147638

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  7 in total

Review 1.  Reconsidering Guidelines on the Use of Pneumococcal Vaccines in Adults 65 Years or Older.

Authors:  Michael Hochman; Pieter A Cohen
Journal:  JAMA Intern Med       Date:  2015-12       Impact factor: 21.873

2.  Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.

Authors:  Daniel M Musher; Maria B Rodriguez-Barradas
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

Authors:  Marc J M Bonten; Susanne M Huijts; Marieke Bolkenbaas; Chris Webber; Scott Patterson; Samantha Gault; Cornelis H van Werkhoven; Anna M M van Deursen; Elisabeth A M Sanders; Theo J M Verheij; Michael Patton; Anne McDonough; Anita Moradoghli-Haftvani; Helen Smith; Tracey Mellelieu; Michael W Pride; Graham Crowther; Beate Schmoele-Thoma; Daniel A Scott; Kathrin U Jansen; Rita Lobatto; Bas Oosterman; Nils Visser; Esther Caspers; Andre Smorenburg; Emilio A Emini; William C Gruber; Diederick E Grobbee
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

4.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Tamara Pilishvili; Catherine Lexau; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Arthur Reingold; Ann Thomas; William Schaffner; Allen S Craig; Philip J Smith; Bernard W Beall; Cynthia G Whitney; Matthew R Moore
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

5.  Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

Authors:  Nick J Andrews; Pauline A Waight; Robert C George; Mary P E Slack; Elizabeth Miller
Journal:  Vaccine       Date:  2012-09-18       Impact factor: 3.641

Review 6.  Pneumococcal Prevention Gets Older and Wiser.

Authors:  Anne Schuchat
Journal:  JAMA Intern Med       Date:  2015-12       Impact factor: 21.873

7.  Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program.

Authors:  Matthew R Moore; Cynthia G Whitney
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883
  7 in total
  1 in total

1.  What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?

Authors:  A T Newall
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.